CalciMedica (CALC) Competitors $1.76 -0.05 (-2.76%) As of 10:50 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CALC vs. CCCC, ANIX, COYA, MIST, GNLX, ZNTL, OCX, CRBU, LXEO, and CRBPShould you be buying CalciMedica stock or one of its competitors? The main competitors of CalciMedica include C4 Therapeutics (CCCC), Anixa Biosciences (ANIX), Coya Therapeutics (COYA), Milestone Pharmaceuticals (MIST), Genelux (GNLX), Zentalis Pharmaceuticals (ZNTL), OncoCyte (OCX), Caribou Biosciences (CRBU), Lexeo Therapeutics (LXEO), and Corbus Pharmaceuticals (CRBP). These companies are all part of the "pharmaceutical products" industry. CalciMedica vs. Its Competitors C4 Therapeutics Anixa Biosciences Coya Therapeutics Milestone Pharmaceuticals Genelux Zentalis Pharmaceuticals OncoCyte Caribou Biosciences Lexeo Therapeutics Corbus Pharmaceuticals C4 Therapeutics (NASDAQ:CCCC) and CalciMedica (NASDAQ:CALC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability. Is CCCC or CALC more profitable? CalciMedica has a net margin of 0.00% compared to C4 Therapeutics' net margin of -313.35%. C4 Therapeutics' return on equity of -42.45% beat CalciMedica's return on equity.Company Net Margins Return on Equity Return on Assets C4 Therapeutics-313.35% -42.45% -27.55% CalciMedica N/A -164.24%-103.53% Do institutionals & insiders hold more shares of CCCC or CALC? 78.8% of C4 Therapeutics shares are owned by institutional investors. 8.7% of C4 Therapeutics shares are owned by insiders. Comparatively, 41.5% of CalciMedica shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has better earnings & valuation, CCCC or CALC? CalciMedica has lower revenue, but higher earnings than C4 Therapeutics. CalciMedica is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioC4 Therapeutics$39.78M2.61-$132.49M-$1.47-0.99CalciMedicaN/AN/A-$34.36M-$1.56-1.13 Which has more volatility & risk, CCCC or CALC? C4 Therapeutics has a beta of 2.93, suggesting that its share price is 193% more volatile than the S&P 500. Comparatively, CalciMedica has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500. Do analysts rate CCCC or CALC? C4 Therapeutics presently has a consensus target price of $12.00, suggesting a potential upside of 721.92%. CalciMedica has a consensus target price of $18.00, suggesting a potential upside of 922.73%. Given CalciMedica's stronger consensus rating and higher probable upside, analysts clearly believe CalciMedica is more favorable than C4 Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score C4 Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50CalciMedica 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to CCCC or CALC? In the previous week, CalciMedica had 2 more articles in the media than C4 Therapeutics. MarketBeat recorded 3 mentions for CalciMedica and 1 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 1.83 beat CalciMedica's score of 0.93 indicating that C4 Therapeutics is being referred to more favorably in the media. Company Overall Sentiment C4 Therapeutics Very Positive CalciMedica Positive Does the MarketBeat Community favor CCCC or CALC? C4 Therapeutics received 9 more outperform votes than CalciMedica when rated by MarketBeat users. However, 94.74% of users gave CalciMedica an outperform vote while only 38.57% of users gave C4 Therapeutics an outperform vote. CompanyUnderperformOutperformC4 TherapeuticsOutperform Votes2738.57% Underperform Votes4361.43% CalciMedicaOutperform Votes1894.74% Underperform Votes15.26% SummaryC4 Therapeutics beats CalciMedica on 9 of the 16 factors compared between the two stocks. Get CalciMedica News Delivered to You Automatically Sign up to receive the latest news and ratings for CALC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CALC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CALC vs. The Competition Export to ExcelMetricCalciMedicaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$24.59M$6.92B$5.60B$8.61BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-1.638.8427.2219.97Price / SalesN/A255.17408.95152.58Price / CashN/A65.8538.2534.64Price / Book1.246.587.114.68Net Income-$34.36M$144.20M$3.24B$248.05M7 Day Performance4.77%3.32%2.47%2.40%1 Month Performance-12.44%10.53%8.66%6.14%1 Year Performance-65.22%3.63%31.22%13.62% CalciMedica Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CALCCalciMedica2.7949 of 5 stars$1.76-2.8%$18.00+922.7%-65.4%$24.59MN/A-1.6330News CoverageCCCCC4 Therapeutics2.2222 of 5 stars$1.33+6.4%$12.00+802.3%-68.7%$94.44M$39.78M-0.78150Positive NewsGap UpANIXAnixa Biosciences3.4683 of 5 stars$2.89+12.5%$9.00+211.4%+30.2%$93.05M$210K-7.415Analyst ForecastHigh Trading VolumeCOYACoya Therapeutics2.2098 of 5 stars$5.55+4.1%$17.00+206.3%-29.6%$92.82M$3.69M-8.546News CoverageAnalyst ForecastMISTMilestone Pharmaceuticals2.4055 of 5 stars$1.73+6.8%$17.00+882.7%+19.4%$92.49M$1M-2.1430Positive NewsGNLXGenelux1.2331 of 5 stars$2.45+1.2%$17.75+624.5%+7.7%$92.45M$8K-2.5810News CoveragePositive NewsGap UpZNTLZentalis Pharmaceuticals2.1938 of 5 stars$1.28+5.8%$8.24+544.1%-85.2%$92.10M$26.87M-0.51160Positive NewsOCXOncoCyte2.8266 of 5 stars$3.19-3.9%$6.06+90.0%-3.6%$91.23M$3.84M-0.90120Positive NewsCRBUCaribou Biosciences3.0501 of 5 stars$0.97-8.0%$8.50+771.9%-39.2%$90.67M$9.92M-0.59100Analyst RevisionLXEOLexeo Therapeutics3.5463 of 5 stars$2.72flat$18.50+580.1%-74.3%$90.30M$650K-0.8658Positive NewsCRBPCorbus Pharmaceuticals4.1357 of 5 stars$7.34-1.1%$50.88+593.1%-82.2%$89.82MN/A-1.5740Positive News Related Companies and Tools Related Companies C4 Therapeutics Alternatives Anixa Biosciences Alternatives Coya Therapeutics Alternatives Milestone Pharmaceuticals Alternatives Genelux Alternatives Zentalis Pharmaceuticals Alternatives OncoCyte Alternatives Caribou Biosciences Alternatives Lexeo Therapeutics Alternatives Corbus Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CALC) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredBillionaires are piling into this gold investmentBillionaires Are Piling into a Special Gold Investment With record gold prices, everyday Americans are scra...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CalciMedica, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CalciMedica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CALC Stock Free CALC Stock Alerts